
MEDIA RELEASE

Ypsomed: Adaptation of Pen Production Capacity – Expanding and Optimizing the European Diabetes Sales Organisation

Burgdorf, 24th February 2010, 7:30am – The Ypsomed Group will be adapting its structure for the manual assembly of pens and production-related support functions due to changes in the product mix and increased automation within pen manufacturing. As of March 2010 a total of 48 jobs in Burgdorf and Solothurn will be affected. In the diabetes business, however, Ypsomed is strengthening its European sales organization for the blood glucose monitoring system mylife™ Pura™ and for the world's first insulin patch pump, mylife™ OmniPod®. Ypsomed has founded a new subsidiary Ypsomed Ltd. in the United Kingdom and is planning an additional 20 sales staff for the mylife™ Diabetescare business within the next six months on top of its approximately 200 already existing European staff. Within a business process optimization program, all call center functions in Germany will newly be centralized in Liederbach, Ypsomed's headquarters near Frankfurt.

Adapting the production capacity to accommodate the changing pen system product mix

Due to the further decreasing order volumes from Sanofi-Aventis for the pen systems OptiPen® Pro, OptiClik® and OptiSet® and because the future manufacturing of the newly planned pen systems will increasingly be automated, Ypsomed is adapting its production capacity. Therefore, 48 jobs will be reduced as of March 2010 in the area of manually performed pen system assembly, component manufacturing and production support functions. Of Ypsomed's total of 1'250 employees, 13 employees in Solothurn and 35 in Burgdorf will be affected. Ypsomed will carry out the reduction in a socially responsible manner and is working out a social plan for the employees concerned. The plan will include compensation for reduced salary payments, an internal job center as well as support in career reorientation. Ypsomed is involving the employee representatives within the ongoing consultation process and works closely with the governmental bodies.

Expanding and Optimizing European Diabetes Sales Organisation

Ypsomed enjoys a decade long diabetes competence and owns the largest independent European sales organization specialized in diabetes. Under its mylife™ Diabetescare brand, which was launched last year, Ypsomed is selling the mylife™ Pura™ blood glucose monitoring system and the mylife™ Clickfine® pen needles as well as from mid-2010 the Clickfine® AutoProtect™ safety pen needle and the mylife™ OmniPod®, the world's first insulin patch pump. Ypsomed is therefore further strengthening its diabetes business sales organization and is planning to add around 20 new sales employees over the next six months. In addition, Ypsomed has founded a new subsidiary, Ypsomed Ltd., in the United Kingdom. In order to increase the operational efficiency in Germany, the call center and back-office functions today performed in Hamburg will be integrated at Ypsomed's German headquarters in Liederbach near Frankfurt by the end of May 2010. The DiaExpert shop will remain in Hamburg.

About the Ypsomed Group

Ypsomed is a leading independent developer and manufacturer of injection systems for self medication and a renowned diabetes care specialist with a track record of more than 25 years. Ypsomed is known as an innovation and technology leader holding around 300 patent families and is the preferred partner to pharmaceutical and biotech companies in the area of self medication. Ypsomed emerged in 2003 from the well-known Disetronic Group with at the time 550 employees and today employs approximately 1'200 employees. Ypsomed is headquartered in Burgdorf (Switzerland) and operates manufacturing locations in Burgdorf, Solothurn, Grenchen and the Czech Republic as well as specialized diabetes sales subsidiaries in Germany, France, Switzerland, the Netherlands and the Nordic countries as well as in India and starting in April 2010 in the United Kingdom.

Further information is available from Daniel Kusio, Head of Investor & Public Relations at Ypsomed Holding AG. Tel. +41 34 424 41 43 or Tel. +41 34 424 41 11. This media release is available in electronic form at www.ypsomed.com (www.ypsomed.com/en/company/123.html).